NYSE:BHVN

Biohaven Pharmaceutical Holding Company Stock Insider Trading

Healthcare > Biotechnology

Buy BHVN

*Your capital is at risk

$14.54

-0.120 (-0.82%)

At Close: Aug 10, 2026

Biohaven Pharmaceutical Holding Company Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.83. In total, the insiders bought 8.16M and sold 46.19K BHVN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.83
● Buy	8.16M shares
● Sell	46.19K shares
87% Buy Activity Weak Positive Correlation
Buy Signal High Confidence Jul 09, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 99.83. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (87% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
May 05, 2025 Buy	Stock Options (Right to buy) A-Award	Gregory Julia P Director	Director	31 716 Value: $717.4K
May 05, 2025 Buy	Stock Options (Right to buy) A-Award	Mehta Kishan Director	Director	31 716 Value: $717.4K
May 05, 2025 Buy	Stock Options (Right to buy) A-Award	Bailey Gregory Director	Director	31 716 Value: $717.4K
May 05, 2025 Buy	Stock Options (Right to buy) A-Award	Heffernan Michael Thomas Director	Director	31 716 Value: $717.4K
May 05, 2025 Buy	Stock Options (Right to buy) A-Award	Antonijevic Irina Director	Director	31 716 Value: $717.4K
Mar 04, 2025 Buy	Common Shares P-Purchase	Childs John W Director	Director	28 400 Value: $864.1K
Mar 04, 2025 Buy	Common Shares P-Purchase	Childs John W Director	Director	25 000 Value: $759.6K
Mar 04, 2025 Buy	Common Shares P-Purchase	Childs John W Director	Director	3 400 Value: $104.5K
Mar 04, 2025 Buy	Common Shares P-Purchase	Childs John W Director	Director	900 Value: $27.7K
Mar 04, 2025 Buy	Common Shares P-Purchase	Childs John W Director	Director	3 400 Value: $104.5K
Mar 04, 2025 Buy	Common Shares P-Purchase	Childs John W Director	Director	3 400 Value: $104.5K
Mar 04, 2025 Buy	Common Shares P-Purchase	Childs John W Director	Director	900 Value: $27.7K
Mar 04, 2025 Buy	Common Shares P-Purchase	Childs John W Director	Director	3 400 Value: $104.5K
Mar 04, 2025 Buy	Common Shares P-Purchase	Childs John W Director	Director	25 000 Value: $759.6K
Jan 05, 2025 Buy	Stock Options (Right to buy) A-Award	Car Bruce Chief Scientific Officer	Officer	112 000 Value: $4.33M
Jan 05, 2025 Buy	Restricted Share Unit Award A-Award	Car Bruce Chief Scientific Officer	Officer	19 000 Value: $276.3K
Jan 05, 2025 Buy	Restricted Share Unit Award M-Exempt	Car Bruce Chief Scientific Officer	Officer	4 750 Value: $69.1K
Jan 05, 2025 Buy	Common Shares M-Exempt	Car Bruce Chief Scientific Officer	Officer	4 750 Value: $69.1K
Jan 05, 2025 Sell	Common Shares F-InKind	Car Bruce Chief Scientific Officer	Officer	2 331 Value: $90.1K
Jan 05, 2025 Buy	Common Shares M-Exempt	Gentile Kimberly SVP, Clinical Operations	Officer	3 750 Value: $54.5K
Jan 05, 2025 Sell	Common Shares F-InKind	Gentile Kimberly SVP, Clinical Operations	Officer	1 956 Value: $75.6K
Jan 05, 2025 Buy	Stock Options (Right to buy) A-Award	Gentile Kimberly SVP, Clinical Operations	Officer	91 000 Value: $3.52M
Jan 05, 2025 Buy	Restricted Share Unit Award A-Award	Gentile Kimberly SVP, Clinical Operations	Officer	15 000 Value: $218.1K
Jan 05, 2025 Buy	Restricted Share Unit Award M-Exempt	Gentile Kimberly SVP, Clinical Operations	Officer	3 750 Value: $54.5K
Jan 05, 2025 Buy	Common Shares M-Exempt	Clark George C. Vp, Chief Accounting Officer	Officer	2 500 Value: $36.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as re...

Read Full Profile Here